Dextrose monohydrate Injection, USP is indicated as a source of water and calories.

Dehydration

Weakness

• As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.

Side effects are rare and are related to injection-

• Phlebitis
• Pain at injection site

Phlebitis

Pain at injection site

• Dextrose monohydrate Injection, USP should not be administered simultaneously with blood through the same administration set because of the possibility of pseudo-agglutination or hemolysis.
• The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema.
• The risk of dilutive states is inversely proportional to the electrolyte concentrations of the injections.
• The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.
• Excessive administration of dextrose injections may result in significant hypokalemia. In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.